The market is projected at $3.08 billion by 2030. The two procedures inside that number have not behaved the same way at all.
The Business Research Company has a new forecast out. Spine augmentation systems: $2.14 billion this year, $2.31 billion next, $3.08 billion by 2030. That works out at 7.6% a year. The drivers are the familiar ones. Aging populations. Osteoporosis. Minimally invasive technique. Better cements. More outpatient work. All of that is real. But spine augmentation is not a young category, and the path it took to get here explains more about where it goes next than any of those drivers do.
In 2009 the New England Journal published two sham-controlled trials of vertebroplasty. Neither found it beat placebo for pain, and the AAOS came out against the procedure the following year. Kyphoplasty fared better: the FREE trial, published the same year, found balloon kyphoplasty effective against non-surgical care, though it was open-label.
The Medicare numbers track that split almost exactly. In the most recent national data published, covering 2012 to 2017, vertebroplasty volume dropped 48%, from 5,744 procedures to 2,987. Kyphoplasty fell only 12.7%, from 24,986 to 21,681. Two procedures, one evidence base each, and the market moved accordingly. Worth noting what did rise over the same five years. Payments to surgeons for kyphoplasty roughly doubled, from an average of $895 to $1,764. That tells you nothing directly about what hospitals paid for cement and balloons, but it does tell you the procedure was becoming scarcer and better compensated at once. Categories in expansion do not usually look like that.
Which is why the forecast can still be right. The clinical argument has been running for fifteen years and has not closed. ISASS, which advocates for the field, points to VERTOS II, VAPOUR and VOPE as the strongest support for vertebroplasty in properly selected patients — VAPOUR carrying the most weight, since it was double-blind and placebo-controlled where VERTOS II was open-label. The dispute has always been about selection: the negative trials included older fractures, the positive ones did not.
And the untreated pool is enormous. Roughly 700,000 osteoporotic compression fractures are diagnosed in the US each year, with an estimated two thirds of vertebral body fractures never picked up at all. Growth outside the US, where populations are aging fast and penetration is low, could carry the whole number on its own.
That divergence is the useful part of the story. Same patients, same fractures, same aging population — and one procedure lost half its volume while the other barely moved. What separated them was the trial data, not the demographics. Growth in this market has never come from the number of fractures. It comes from what the evidence permits.
###
Legal Disclaimer:
Content published on SPINEMarketGroup (thespinemarketgroup.com) is provided for informational purposes only and on an “as is” basis, without warranties of any kind. We do not guarantee the accuracy, completeness, legality, or reliability of any information, images, videos, links, or third-party materials featured on the site. Any views or claims expressed in contributed content or press releases belong to their respective authors or sources. For copyright concerns, factual corrections, or content-related complaints, please contact us directly for review.